BAP PHARMA GROUP LIMITED
Get an alert when BAP PHARMA GROUP LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£31m
+248% highest in 3 filed years
Net assets
£93m
+30% highest in 3 filed years
Employees
107
+15.1% highest in 3 filed years
Profit before tax
£25m
+73.7% highest in 3 filed years
Net assets
3-year trend · vs Industrials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £270,072,616 | £181,175,435 | £263,663,543 | +45.5% | |
| Operating profit | £15,078,184 | £13,869,807 | £23,657,323 | +70.6% | |
| Profit before tax | £15,719,689 | £14,561,892 | £25,289,299 | +73.7% | |
| Net profit | £11,859,107 | £10,676,937 | £20,018,306 | +87.5% | |
| Cash | £4,461,798 | £9,012,814 | £31,368,835 | +248% | |
| Total assets less current liabilities | £61,175,978 | £71,287,216 | £93,036,405 | +30.5% | |
| Net assets | £60,938,675 | £71,180,339 | £92,527,642 | +30% | |
| Equity | £60,938,675 | £71,180,339 | £92,527,642 | +30% | |
| Average employees | 78 | 93 | 107 | +15.1% | |
| Wages | £5,738,916 | £6,672,705 | £7,507,763 | +12.5% | |
| Directors' remuneration | £120,000 | £120,000 | £72,833 | -39.3% | |
| Directors' pension contributions | £80,000 | £100,000 | £60,000 | -40% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 5.6% | 7.7% | 9.0% | |
| Net margin | 4.4% | 5.9% | 7.6% | |
| Return on capital employed | 24.6% | 19.5% | 25.4% | |
| Gearing (liabilities / total assets) | 22.5% | 25.1% | 17.1% | |
| Current ratio | 4.24x | 3.17x | 4.81x | |
| Interest cover | — | 33.06x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- Crowe U.K. LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Accordingly, the Directors consider that there are no material uncertainties related to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the relevant entity's ability to continue as a going concern.”
Group structure
- BAP PHARMA GROUP LIMITED · parent
- BAP Pharma Holdings Limited 100%
- BAP Pharma Limited 100%
- BAP US Inc. 100%
- BAP Pharma GmbH 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PARKAR, Bashir Ahmed, Dr | Director | 2015-08-13 | Jun 1959 | British |
| PARKAR, Nafisa | Director | 2015-08-21 | Aug 1962 | British |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COWAN, Graham | Director | 2015-08-13 | 2015-08-13 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Nafisa Parkar | Individual | Shares 25–50%, Voting 25–50%, Appoints directors, Appoints directors (as trust), Appoints directors (as firm) | 2016-07-01 | Active |
| Dr Bashir Ahmed Parkar | Individual | Shares 50–75%, Voting 50–75%, Appoints directors, Appoints directors (as trust), Appoints directors (as firm), Significant influence, Significant influence (as trust), Significant influence (as firm) | 2016-07-01 | Active |
Filing timeline
Last 20 of 35 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-10-06 | AA | accounts | Accounts with accounts type group | |
| 2026-09-17 | RP01PSC01 | miscellaneous | Legacy | |
| 2026-08-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-08-14 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2025-09-10 | AA | accounts | Accounts with accounts type group | |
| 2025-08-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-21 | AA | accounts | Accounts with accounts type group | |
| 2024-08-12 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-07-02 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2023-10-03 | AA | accounts | Accounts with accounts type group | |
| 2023-08-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-09-20 | AA | accounts | Accounts with accounts type group | |
| 2022-08-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-08 | AD01 | address | Change registered office address company with date old address new address | |
| 2021-09-21 | AA | accounts | Accounts with accounts type group | |
| 2021-08-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-08-12 | CH01 | officers | Change person director company with change date | |
| 2020-08-20 | AA | accounts | Accounts with accounts type group | |
| 2020-08-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2019-08-23 | AA | accounts | Accounts with accounts type group |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Spotted an error, or named here and want to reply? Report it · How we handle corrections